Stay updated with breaking news from Lantern Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
They will use expanded mutational signature analyses to identify new biomarker-defined indications in multiple tumor types.
Lantern Pharma the US National Institutes of Health unit NCI's DTB have extensed oncology collaboration for clinical trials for LP-184 and LP-284.
/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform...
Get to know the finalists in the 2022 Innovation Awards, brought to you by D CEO and Dallas Innovates. Winners will be revealed Jan. 12.
/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform...